Drug Trial Radar · NCT05125068
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
Last checked: Nov 19, 2026Latest source record: Mar 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
24
Actual
Start
Mar 21, 2022
Primary completion
Jul 31, 2023
Study completion Jul 31, 2023
Sponsor
- Lead sponsor
- Eledon PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.
Conditions
- IgA Nephropathy
- IgAN
Interventions
AT-1501Drug
AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy - change in participants UPCRTime frame: Up to 24 weeks
- Safety- Number of participants with treatment related adverse eventsTime frame: Through study completion, an average of 100 weeks
Locations
26 sites in 10 countries. Site status is shown where the registry gives one.
Liverpool Hospital
Liverpool, South Wales, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Western Health
St Albans, Victoria, Australia
University Hospital Centre Sisters of Charity
Zagreb, Croatia
University Hospital Dubrava Zagreb
Zagreb, Croatia
University Malaya Medical Centre (UMMC)
Kuala Lumpur, Kuala Lumpur WP, Malaysia
Hospital Tengku Ampuan Afzan (HTAA)
Kuantan, Pahang, Malaysia
Hospital Queen Elizabeth
Kota Kinabalu, Sabah, Malaysia
Hospital Kajang
Kajang, Selangor, Malaysia
Hospital Serdang
Kajang, Selangor, Malaysia
Waikato Hospital
Hamilton, New Zealand
Hawke's Bay Hospital
Hastings, New Zealand
University of Santo Tomas Hospital
Sampaloc, Manila, Philippines
Medical University of Bialystok UI
Bialystok, Poland
Specjalistyczne Centrum Medyczne, SCM Spółka
Krakow, Poland
Hospital Clinico San Carlos
Madrid, Spain
Hospital Virgen de la Macarena
Seville, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
Hospital de Sagunto
Sagunto, Valencia, Spain
National Hospital of Sri Lanka
Colombo, Sri Lanka
Sri Jayawardanepura General Hospital
Nugegoda, Sri Lanka
Phramongkutklao Hospital
Bangkok, Thailand
Chiang Mai University
Chiang Mai, Thailand
Prince of Songkla University
Dusit, Bangkok, Thailand
Chulalongkorn University
Pathum Wan, Bangkok, Thailand
Kings College Hospital
Camberwell, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.